Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 51 people across three groups: 19 received oral valganciclovir (an antiviral tablet), 15 received topical ganciclovir 2% (an antiviral eye drop), and 17 received a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in the amount of a virus called CMV (cytomegalovirus) detected inside the eye, as well as whether participants' eye inflammation settled down by the end of the study. Not everyone completed the trial — all 19 in the oral tablet group finished, while 2 people in each of the other two groups did not complete it. The reported data shows that the primary measurement — the reduction in CMV virus levels inside the eye after 7 days — differed across the three groups. Virus levels in the oral valganciclovir group dropped by an average of 0.59 units (on a logarithmic scale, meaning roughly a fourfold reduction), the topical ganciclovir group dropped by 0.23 units, and the placebo group dropped by 0.04 units. For the secondary outcome looking at how many participants reached a state of reduced eye inflammation by the final visit, the reported data shows the numbers were 19 out of 19 in the oral tablet group, 13 out of 13 in the eye drop group, and 15 out of 15 in the placebo group — meaning all participants who completed the trial were counted in this outcome. Regarding the effect of steroid eye drops used before the trial started, the reported data shows the same figure (0.10 IU/mL) across all three groups, though no further breakdown of what this means was provided in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31862739) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your doctor believes you have a type of eye inflammation called CMV anterior uveitis (swelling at the front of the eye linked to a virus called cytomegalovirus).
- A lab test (PCR) has come back positive for CMV in your eye, OR you have had a confirmed CMV eye infection in the past proven by a PCR test.
- You are willing to use an accepted form of contraception (such as medication, a device, or barrier method) or to abstain from sex during the study period.
Who may not be able to join:
- You are under 18 years of age.
- Your eye inflammation affects deeper parts of the eye, such as the jelly-like fluid inside, the layer behind the eye, or the retina.
- You have taken antiviral medication within the last 14 days before joining the study.
- You have had a steroid injection in or around your eye within the past 8 weeks.
- You are currently taking steroid tablets by mouth.
- Your immune system is weakened, either due to a medical condition or medication.
- You have taken medication that suppresses the immune system in the past 6 months.
- Your PCR test result came back negative for CMV.
- Your PCR test came back positive for a different virus called herpes simplex (HSV) or varicella zoster (VZV).
- You are pregnant, breastfeeding, or planning to become pregnant during the study (a pregnancy test is required for all women of childbearing age within 4 weeks before joining).
- Your blood test results show that certain blood cell counts or platelet counts are below the normal range for the laboratory used.
- Your blood test results show that your kidney function measurements (BUN or creatinine) are above the normal range for the laboratory used.
- You have had eye surgery in the past 30 days, or have eye surgery planned within the next 45 days.
- You have a condition affecting your whole body's immune system, or another eye condition (besides the anterior uveitis) that would affect your treatment during the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in CMV Viral Load
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.